Skip To Main Content
Julia Lostes Bardaji on Muck Rack

Julia Lostes Bardaji

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Julia Lostes

Contact Julia Lostes, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

|
By Ignacio Melero, Alexandra Epp, Nicole A. Kratochwil, Chun Lin Wu, Michael Hettich, Natascha Rieder, Petra C. Schwalie, Solveig Badillo, Nadine Kumpesa, Andreas Thommen, Danielle J. Vugts, Victor Moreno, Eduardo Álvarez Verified, Carlos de Andrea, Iben Spanggaard, Dae Ho Lee, James B. Spicer, Fiona Thistlethwaite, Do-Youn Oh, Antoine Hollebecque, Stefan N. Symeonides, Bernhard Reis, Corinne Rusterholz, Georgios Kazantzidis, Julia Lostes Bardaji, Olivera Cirovic
| Nature Verified
Abstract CD40 activation on dendritic cells (DCs) enhances tumor antigen cross-priming of tumor-specific cytotoxic T lymphocytes, strengthening anticancer immune responses. RO7300490 is a fibroblast activation protein (FAP)-targeted CD40 agonist antibody. In this phase I study, 80 patients with advanced and/or metastatic solid tumors received RO7300490 biweekly (dose range 16–1,100 mg). The primary objective was to evaluate safety and tolerability.
Open in Who Shared Issue with article?
See all 1 articles